

[View this email in your browser](#)

Public Newsletter 2020



Mobilise-D will develop and validate body-worn technology to assess patients' daily life mobility, focusing on different conditions that often affect mobility (COPD, PD, MS, hip fracture), with the goal to improve follow-up and personalized care of patients.



The European Medicines Agency letter of support for Mobilise-D

This public support from EMA endorses our initial stage in the wider objective to pursue the qualification of Digital Mobility Outcomes (DMOs) as monitoring biomarkers of mobility performance in regulatory drug trials. Read more [HERE](#).




The Innovative Medicines Initiative (IMI) article

IMI acknowledges the Mobilise-D Consortium work: «One step closer: digital readouts of walking as a measure of health». Read more [HERE](#).



Mobilise-D Videos

We made 6 videos in 2020, with «Why Mobility matters - now more than ever» as the most viewed. Check out all our videos on our [YouTube channel](#).



Mobilise-D Publications

In 2020, we had no less than 12 publications. Three of them were major core Mobilise-D publications. See all our publications [HERE](#).



NIHR highlights Mobilise-D as how to do clinical research during COVID

The National Institute for Health Research, UK, featured us as a case study for how to start-up research again, despite the ongoing global pandemic. Read the article [HERE](#).



Important milestone reached for the Technical Validation Study

The Technical Validation Study officially started recruiting patients in August and reached 60% recruitment by the end of 2020. Read more [HERE](#).



Real World Stories - Episode 1

Read how our «[Why Mobility matters](#)» video had a direct impact on Gottfried's daily life during the COVID-19 pandemic [HERE](#).

First IMI review meeting - under COVID-19 lockdown, Oct. 2020

The independent international reviewers praised our impressive work! Despite hiccups such as Brexit, COVID, lockdowns, and cyber-attacks, the consortium found the balance needed to continue the work and create continuous results as planned.



Follow us on Social Media!

[@Mobilise_D](#)



Mobilise-D has received funding from IMI 2 Joint Undertaking under grant agreement No. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Copyright © 2021 Mobilise-D, All rights reserved.

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

